Drug Approval | April 10, 2024
Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
The product will be launched in March 2024
It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation
The Pregabalin capsules has a market size of ~US$248 mn per IQVIA
Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis
The product is expected to be launched in December 2023
The product will be manufactured at Lupin's Pithampur facility in India
Pantoprazole Sodium Delayed-Release Tablets are indicated for short-term treatment of Erosive Esophagitis associated with GERD
Subscribe To Our Newsletter & Stay Updated
